. Author manuscript; available in PMC: 2017 Mar 1.

Published in final edited form as: Ophthalmology. 2015 Dec 11;123(3):497–504. doi: 10.1016/j.ophtha.2015.10.043

Table 3.

Time Implications for Ocular Surface Squamous Neoplasia Treated Surgically Versus Medically in the First Year.

Time implications^*	Surgical	Medical	P value
# visits to BPEI, actual, mean±SD, (median, range)	5.2±1.6 (5, 2–9)	8.6±4.3 (7, 3–23)	<0.005
# visits to BPEI, imputed^† mean±SD, (median, range)	6.4±2.0 (6, 2–10)	9.3±4.3 (8, 4–26)	<0.005
Hospital Billing Charges for Clinic Visits (actual) ^°	$1,3112±507 ($1,236, $309–2,472)	$3,058±1,321 ($2,572, $1,336–7,516)	<0.005
Medicare Allowable Charges for Clinic Visits (actual) ^‡	$547±211 (515.5,128.9–1,031)	$1,288± 551 ($1,085.7, $570.2–$3,147.8)	<0.005

n=number of patient in each group who incurred a cost in each category; SD=standard deviation; BPEI=Bascom Palmer Eye Institute

Visits including day of surgery or clinic day that interferon therapy was initiated.

^†

General follow up for surgery: 4 visits between zero to 3 months, and 1 visit between 3 to 6 month, 6 to 9 month, and 9 to 1 year windows. In patients with less than 1 year follow up, visits imputed to fit this general pattern. For example, a patient with 6 months of follow up would have 2 additional visits added. General follow up for medical group, once tumor resolved, follow every 3 months. In patients with less than 1 year follow up, visits imputed to fit this general pattern.

^°

Based upon hospital charges for an office visit based on hospital billing for:

Level 3 new patient (facility and physician fee): $409
Level 3, returning patient (facility and physician fee): $309

^‡

Based on 2013 Medicare allowable charges for an office visit:

Level 3 new patient (facility and physician fee): $183.55
Level 3, returning patient (facility and physician fee): $128.88